These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 9854634)
1. [New data on the pharmacokinetics of aminostigmine]. Prozorovskiĭ VB; Chepur SV; Vorob'ev-Desiatovskiĭ NV; Panov PB Eksp Klin Farmakol; 1998; 61(5):46-9. PubMed ID: 9854634 [TBL] [Abstract][Full Text] [Related]
2. [The toxicological characteristics of the interaction of cholinolytics with aminostigmine--a new reversible cholinesterase inhibitor]. Prozorovskiĭ VB; Sazonova AV Eksp Klin Farmakol; 1995; 58(5):57-61. PubMed ID: 8704593 [TBL] [Abstract][Full Text] [Related]
3. [Aminostigmine-a novel drug against home poisoning]. Bonitenko II; Safronov GA; Sosiukin AE; Pershin VN; Shpilenia LS Klin Med (Mosk); 1996; 74(8):58-61. PubMed ID: 9036214 [TBL] [Abstract][Full Text] [Related]
4. [The pharmacological characteristics of the new anticholinesterase drug aminostigmine]. Prozorovskiĭ VB; Pavlova LV; Suslova IM; Shchemeleva NI Eksp Klin Farmakol; 1992; 55(1):13-6. PubMed ID: 1305425 [TBL] [Abstract][Full Text] [Related]
5. [Biochemical characteristics of aminostigmine--a new anticholinesterase agent]. Prozorovskiĭ VB; Rozengart VI; Ardab'eva TV; Kugusheva LI; Suslova IM Biokhimiia; 1996 Apr; 61(4):690-6. PubMed ID: 8724787 [TBL] [Abstract][Full Text] [Related]
6. [Acceleration of the restoration of conditioned reflexes following anesthesia using aminostigmine]. Prozorovskiĭ VB; Iudkina NI Anesteziol Reanimatol; 1991; (1):25-6. PubMed ID: 1862957 [TBL] [Abstract][Full Text] [Related]
7. [Aminostigmine as a cholinesterase inhibitor and as an agent for treating poisonings by cholinergic blockers]. Prozorovskiĭ VB; Livanov GA; Velikova VD; Afanas'ev VV; Pavlova LV Eksp Klin Farmakol; 1994; 57(5):13-5. PubMed ID: 7696893 [TBL] [Abstract][Full Text] [Related]
8. [Histamine blockers increase efficacy of specific antidote prophylaxis of intoxication by cholinesterase inhibitors in mice]. Prozorovskiĭ VB; Skopichev VG; Ditiateva ZhA; Sazonova AV Eksp Klin Farmakol; 2000; 63(4):64-7. PubMed ID: 11022312 [TBL] [Abstract][Full Text] [Related]
9. [The comparative clinico-experimental characteristics of aminostigmine and galanthamine used for treating poisonings by choline-blocking substances]. Prozorovskiĭ VB; Velikova VD; Pshenkina NN; Vasilenko ET Eksp Klin Farmakol; 1996; 59(1):64-7. PubMed ID: 8704639 [TBL] [Abstract][Full Text] [Related]
10. [Bizerine: new anticholinesterase drug with selective gastrointestinal action]. Prozorovskiĭ VB; Pavlova LV; Suslova IM; Sazonova AV; Shchemeleva NI Eksp Klin Farmakol; 2010 Aug; 73(8):14-6. PubMed ID: 20919551 [TBL] [Abstract][Full Text] [Related]
11. Possibility of usage of aminostigmine structural analogue for the treatment of toxic cognitive disorders. Fateev IV; Subbotina SN; Kurpyakova AF; Tyunin MA Bull Exp Biol Med; 2014 Jan; 156(3):353-6. PubMed ID: 24771374 [TBL] [Abstract][Full Text] [Related]
12. [Protection of mice by carbamates cholinesterase inhibitors against poisoning by armin and its dependence on certain physico-chemical indicators]. Prozorovskiĭ VB; Pavlova LV; Suslova IM; Sazonova AV; Kokushkina AV Vopr Med Khim; 1999; 45(6):525-9. PubMed ID: 10761219 [TBL] [Abstract][Full Text] [Related]
13. [The influence of aminostigmine on the parameters of nonspecific resistance and immune system of the organism upon acute poisoning of benzyl 3-quinuclidylate]. Zabrodskiĭ PF; Troshkin NM; Germanchuk VG; Sidel'nikova NM; Lim VG Eksp Klin Farmakol; 2005; 68(6):40-2. PubMed ID: 16405033 [TBL] [Abstract][Full Text] [Related]
14. Acute effects of an insect repellent, N,N-diethyl-m-toluamide, on cholinesterase inhibition induced by pyridostigmine bromide in rats. Chaney LA; Wineman RW; Rockhold RW; Hume AS Toxicol Appl Pharmacol; 2000 Jun; 165(2):107-14. PubMed ID: 10828206 [TBL] [Abstract][Full Text] [Related]
16. Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics. Algorta J; Pena MA; Alvarez A; Maraschiello C; Maruhn D; Windisch M; Mucke HA Int J Clin Pharmacol Ther; 2009 Jul; 47(7):483-90. PubMed ID: 19640356 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of pyridostigmine in a child with postural tachycardia syndrome. Filler G; Gow RM; Nadarajah R; Jacob P; Johnson G; Zhang YL; Christians U Pediatrics; 2006 Nov; 118(5):e1563-8. PubMed ID: 17015495 [TBL] [Abstract][Full Text] [Related]
18. Effect of pyridostigmine, pralidoxime and their combination on survival and cholinesterase activity in rats exposed to the organophosphate paraoxon. Petroianu GA; Nurulain SM; Arafat K; Rajan S; Hasan MY Arch Toxicol; 2006 Nov; 80(11):777-84. PubMed ID: 16598495 [TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetics of huperzine A in rats and mice]. Wang YE; Feng J; Lu WH; Tang XC Zhongguo Yao Li Xue Bao; 1988 May; 9(3):193-6. PubMed ID: 3213536 [No Abstract] [Full Text] [Related]
20. Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260. Molnár AH; Varga C; Janáky T; Tóth G; Tóth G; Farkas J; László F; László FA Regul Pept; 2007 Jun; 141(1-3):12-8. PubMed ID: 17258819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]